Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations

Michael M. Witte, Norman L. Foster, Adam S. Fleisher, Monique M. Williams, Kimberly Quaid, Michael Wasserman, Gail Hunt, J. Scott Roberts, Gil D. Rabinovici, James L. Levenson, Ann Hake, Craig A. Hunter, Luann E. Van Campen, Michael J. Pontecorvo, Helen M. Hochstetler, Linda B. Tabas, Paula T. Trzepacz

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detected antemortem. Practitioners and patients need to better understand potential diagnostic benefits and limitations of amyloid-PET and the complex practical, ethical, and social implications surrounding this new technology. To complement the practical considerations, Eli Lilly and Company sponsored a Bioethics Advisory Board to discuss ethical issues that might arise from clinical use of amyloid-PET neuroimaging with patients being evaluated for causes of cognitive decline. To best address the multifaceted issues associated with amyloid-PET neuroimaging, we recommend this technology be used only by experienced imaging and treating physicians in appropriately selected patients and only in the context of a comprehensive clinical evaluation with adequate explanations before and after the scan.

Original languageEnglish
Pages (from-to)358-367
Number of pages10
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume1
Issue number3
DOIs
StatePublished - Sep 1 2015

Fingerprint

Amyloid
Neuroimaging
Positron-Emission Tomography
Alzheimer Disease
Technology
Bioethics
Amyloid Plaques
Ethics
Autopsy
Pathology
Physicians
Cognitive Dysfunction

Keywords

  • Alzheimer's disease
  • Amyloid-β
  • Bioethics in neurology
  • Biomarkers
  • Dementia
  • Diagnostic use
  • Mild cognitive impairment
  • Positron emission tomography

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Clinical use of amyloid-positron emission tomography neuroimaging : Practical and bioethical considerations. / Witte, Michael M.; Foster, Norman L.; Fleisher, Adam S.; Williams, Monique M.; Quaid, Kimberly; Wasserman, Michael; Hunt, Gail; Roberts, J. Scott; Rabinovici, Gil D.; Levenson, James L.; Hake, Ann; Hunter, Craig A.; Van Campen, Luann E.; Pontecorvo, Michael J.; Hochstetler, Helen M.; Tabas, Linda B.; Trzepacz, Paula T.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 1, No. 3, 01.09.2015, p. 358-367.

Research output: Contribution to journalArticle

Witte, MM, Foster, NL, Fleisher, AS, Williams, MM, Quaid, K, Wasserman, M, Hunt, G, Roberts, JS, Rabinovici, GD, Levenson, JL, Hake, A, Hunter, CA, Van Campen, LE, Pontecorvo, MJ, Hochstetler, HM, Tabas, LB & Trzepacz, PT 2015, 'Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 1, no. 3, pp. 358-367. https://doi.org/10.1016/j.dadm.2015.06.006
Witte, Michael M. ; Foster, Norman L. ; Fleisher, Adam S. ; Williams, Monique M. ; Quaid, Kimberly ; Wasserman, Michael ; Hunt, Gail ; Roberts, J. Scott ; Rabinovici, Gil D. ; Levenson, James L. ; Hake, Ann ; Hunter, Craig A. ; Van Campen, Luann E. ; Pontecorvo, Michael J. ; Hochstetler, Helen M. ; Tabas, Linda B. ; Trzepacz, Paula T. / Clinical use of amyloid-positron emission tomography neuroimaging : Practical and bioethical considerations. In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2015 ; Vol. 1, No. 3. pp. 358-367.
@article{8404684d2010471695c8f358d5873ba8,
title = "Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations",
abstract = "Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detected antemortem. Practitioners and patients need to better understand potential diagnostic benefits and limitations of amyloid-PET and the complex practical, ethical, and social implications surrounding this new technology. To complement the practical considerations, Eli Lilly and Company sponsored a Bioethics Advisory Board to discuss ethical issues that might arise from clinical use of amyloid-PET neuroimaging with patients being evaluated for causes of cognitive decline. To best address the multifaceted issues associated with amyloid-PET neuroimaging, we recommend this technology be used only by experienced imaging and treating physicians in appropriately selected patients and only in the context of a comprehensive clinical evaluation with adequate explanations before and after the scan.",
keywords = "Alzheimer's disease, Amyloid-β, Bioethics in neurology, Biomarkers, Dementia, Diagnostic use, Mild cognitive impairment, Positron emission tomography",
author = "Witte, {Michael M.} and Foster, {Norman L.} and Fleisher, {Adam S.} and Williams, {Monique M.} and Kimberly Quaid and Michael Wasserman and Gail Hunt and Roberts, {J. Scott} and Rabinovici, {Gil D.} and Levenson, {James L.} and Ann Hake and Hunter, {Craig A.} and {Van Campen}, {Luann E.} and Pontecorvo, {Michael J.} and Hochstetler, {Helen M.} and Tabas, {Linda B.} and Trzepacz, {Paula T.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.dadm.2015.06.006",
language = "English",
volume = "1",
pages = "358--367",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Clinical use of amyloid-positron emission tomography neuroimaging

T2 - Practical and bioethical considerations

AU - Witte, Michael M.

AU - Foster, Norman L.

AU - Fleisher, Adam S.

AU - Williams, Monique M.

AU - Quaid, Kimberly

AU - Wasserman, Michael

AU - Hunt, Gail

AU - Roberts, J. Scott

AU - Rabinovici, Gil D.

AU - Levenson, James L.

AU - Hake, Ann

AU - Hunter, Craig A.

AU - Van Campen, Luann E.

AU - Pontecorvo, Michael J.

AU - Hochstetler, Helen M.

AU - Tabas, Linda B.

AU - Trzepacz, Paula T.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detected antemortem. Practitioners and patients need to better understand potential diagnostic benefits and limitations of amyloid-PET and the complex practical, ethical, and social implications surrounding this new technology. To complement the practical considerations, Eli Lilly and Company sponsored a Bioethics Advisory Board to discuss ethical issues that might arise from clinical use of amyloid-PET neuroimaging with patients being evaluated for causes of cognitive decline. To best address the multifaceted issues associated with amyloid-PET neuroimaging, we recommend this technology be used only by experienced imaging and treating physicians in appropriately selected patients and only in the context of a comprehensive clinical evaluation with adequate explanations before and after the scan.

AB - Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detected antemortem. Practitioners and patients need to better understand potential diagnostic benefits and limitations of amyloid-PET and the complex practical, ethical, and social implications surrounding this new technology. To complement the practical considerations, Eli Lilly and Company sponsored a Bioethics Advisory Board to discuss ethical issues that might arise from clinical use of amyloid-PET neuroimaging with patients being evaluated for causes of cognitive decline. To best address the multifaceted issues associated with amyloid-PET neuroimaging, we recommend this technology be used only by experienced imaging and treating physicians in appropriately selected patients and only in the context of a comprehensive clinical evaluation with adequate explanations before and after the scan.

KW - Alzheimer's disease

KW - Amyloid-β

KW - Bioethics in neurology

KW - Biomarkers

KW - Dementia

KW - Diagnostic use

KW - Mild cognitive impairment

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84940179269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940179269&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2015.06.006

DO - 10.1016/j.dadm.2015.06.006

M3 - Article

AN - SCOPUS:84940179269

VL - 1

SP - 358

EP - 367

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

IS - 3

ER -